Literature DB >> 23998076

Tackling the problems of tumour chemotherapy by optimal drug scheduling.

Ambili Remesh1.   

Abstract

INTRODUCTION: There are various strategies for overcoming the major pitfalls of cancer chemotherapy, such as toxicity and drug resistance. The scientific computing of drug scheduling by optimisation before drug administration is one among them. In a majority of these strategies, the pharmacodynamic variations are given more importance than the pharmacokinetic variations. This study was meant to analyse the importance of the pharmacokinetic parameters (φ) of the individual patients in cancer chemotherapy scheduling, along with the pharmacodynamic factors.
METHODS: A mathematical model is developed and it is implemented in the open source OCTAVE GNU LINUX. Optimisation is done by using an optimization tool in OCTAVE. The present study was aimed at evaluating the daily drug dosaging and cyclic chemotherapy which are commonly practised in the chemotherapy scheduling. Four cases were analyzed with and without considering the pharmacokinetic parameters. The optimal therapy was meant to reduce the number of cancer cells to a minimum at the end of the therapy and to minimise the emergence of resistant cancer cells. Since the dose was within tolerable limits, the toxic effects could also be minimised.
RESULTS: Even with the consideration of a 1 per cent effect (φ), the maximum possible dose and the performance index were increased in the daily scheduling. But in the cyclic therapy, even though the maximum tolerated dose or the performance index was not altered, the cumulative toxicity was greatly reduced.
CONCLUSION: Daily scheduling and cyclic chemotherapy can be applied alternatively more effectively, by considering the interindividual variations in the pharmacokinetic effect (φ).

Entities:  

Keywords:  Chemotherapy; Daily scheduling; Optimal drug therapy; Pharmacokinetics; Toxicity

Year:  2013        PMID: 23998076      PMCID: PMC3749646          DOI: 10.7860/JCDR/2013/6223.3144

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  15 in total

Review 1.  Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

Authors:  W E Evans; M V Relling
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

2.  Mathematical approaches to optimization of cancer chemotherapy.

Authors:  S Zietz; C Nicolini
Journal:  Bull Math Biol       Date:  1979       Impact factor: 1.758

Review 3.  The use of drugs in combination for the treatment of cancer: rationale and results.

Authors:  V T DeVita; P S Schein
Journal:  N Engl J Med       Date:  1973-05-10       Impact factor: 91.245

4.  Drug kinetics and drug resistance in optimal chemotherapy.

Authors:  M I Costa; J L Boldrini; R C Bassanezi
Journal:  Math Biosci       Date:  1995-02       Impact factor: 2.144

Review 5.  The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

Authors:  K T Kivistö; H K Kroemer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

Review 6.  Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.

Authors:  E Masson; W C Zamboni
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

Review 7.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.

Authors:  H Gurney
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

8.  A history of cancer chemotherapy.

Authors:  Vincent T DeVita; Edward Chu
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

9.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.

Authors:  W E Evans; W R Crom; M Abromowitch; R Dodge; A T Look; W P Bowman; S L George; C H Pui
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

10.  How to calculate the dose of chemotherapy.

Authors:  Howard Gurney
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.